Related Experiment Video

Updated: Apr 4, 2026

Generation of Alginate Microspheres for Biomedical Applications
10:33

Generation of Alginate Microspheres for Biomedical Applications

Published on: August 12, 2012

22.1K

Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized

Pasquale Del Gaudio1, Felicetta De Cicco1, Francesca Sansone1

  • 1Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132, 84084 Fisciano, SA, Italy.

Carbohydrate Polymers
|September 8, 2015
PubMed

Insights

New enteric alginate beads offer personalized omeprazole (OME) dosages for pediatric gastro-esophageal reflux disease (GERD). These beads provide controlled drug release, improving treatment compared to market products.

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Pediatric Medicine

Background:

  • Gastro-esophageal reflux disease (GERD) treatment in children presents challenges with current dosage forms.
  • Need for age- and weight-appropriate medication delivery in pediatric patients.

Purpose of the Study:

  • To formulate enteric alginate beads loaded with omeprazole (OME) for personalized pediatric GERD treatment.
  • To evaluate the drug loading, release kinetics, and in vitro performance of these novel beads.

Main Methods:

  • Omeprazole (OME) was entrapped within SBA-15 mesoporous silica and subsequently loaded into alginate beads via prilling.
  • Characterization of beads for size, morphology, drug loading, and distribution.
  • In vitro release studies were conducted in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF).

Main Results:

  • Alginate beads exhibited homogeneous size, spherical morphology, and consistent drug loading and distribution.
  • Limited swelling and drug release (<10%) were observed in SGF within 2 hours.
  • Prolonged drug release occurred in SIF over 6 hours, indicating suitability for intestinal delivery.
  • The novel beads demonstrated superior performance compared to a marketed product, particularly in SIF release.

Conclusions:

  • The developed enteric alginate beads are a promising novel tool for personalized GERD treatment in children.
  • Uniformity and controlled release properties support their potential for improved pediatric pharmacotherapy.
  • This formulation addresses limitations of existing treatments for pediatric GERD.

Keywords:
Alginate beadsEnteric particlesOmeprazolePaediatric formulationsPrillingSBA-15

More Related Videos

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.2K
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

1.5K

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
403
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
2.6K
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
213
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
220
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
309
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
150